Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 20/20 | 0.60 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.56 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.56 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.56 |
| ▸ | MAPK10 | P53779 | 5/20 | 0.54 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | GCGR | P47871 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5095661 | 0.90 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11MAPK10 | |
| SCHEMBL5091812 | 0.83 | MAPK14 (0.68) | MAPK14MAPK13MAPK12MAPK11MAPK10 | |
| SCHEMBL5091840 | 0.83 | MAPK14 (0.70) | MAPK14MAPK13MAPK12MAPK11MAPK10 | |
| SCHEMBL5095866 | 0.82 | MAPK14 (0.71) | MAPK14MAPK13MAPK12MAPK11MAPK10 | |
| SCHEMBL5097766 | 0.82 | MAPK14 (0.62) | MAPK14MAPK13MAPK12MAPK11MAPK10 | |
| SCHEMBL5098362 | 0.82 | MAPK14 (0.57) | MAPK14MAPK13MAPK12MAPK11MAPK10 | |
| SCHEMBL14033075 | 0.81 | MAPK14 (0.70) | MAPK14MAPK13MAPK12MAPK11MAPK10 | |
| SCHEMBL5091842 | 0.79 | MAPK14 (0.63) | MAPK14MAPK13MAPK12MAPK11MAPK10 | |
| SCHEMBL5104340 | 0.79 | MAPK14 (0.61) | MAPK14MAPK13MAPK12MAPK11MAPK10 | |
| SCHEMBL5104336 | 0.79 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442713-B2 | 2-thio-substituted imidazole derivatives and their use in pharmaceutics | MERCKLE GMBH (DE) | 2008-10-28 | — | — | US | disclosed |
| US-7442713-B2 | 2-thio-substituted imidazole derivatives and their use in pharmaceutics | MERCKLE GMBH (DE) | 2008-10-28 | — | — | US | disclosed |
| US-7442713-B2 | 2-thio-substituted imidazole derivatives and their use in pharmaceutics | MERCKLE GMBH (DE) | 2008-10-28 | — | — | US | disclosed |
| US-20060252810-A1 | 2-Thio-substituted imidazole derivatives and their use in pharmaceutics | LAUFER STEFAN | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252810-A1 | 2-Thio-substituted imidazole derivatives and their use in pharmaceutics | IL2, TPMT, IFNG | MAPK14 3913/4885MAPK13 3863/4885MAPK12 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.